The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 14
- 14 new
- Median first-year cost
- $69,706
- $1,004,552 in all
- Institutions
- 13
- 14 contact PIs
- Patents
- 2
- from 1 funded project
Awards by fiscal year
0
0
14
0
0
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- BRIGHAM AND WOMEN'S HOSPITAL1
- COLUMBIA UNIVERSITY HEALTH SCIENCES1
- GEORGETOWN UNIVERSITY1
and 8 other institutions
Most frequent study sections
- Special Emphasis Panel (ZRG1 BBBP-T (50))14
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2016 | Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice1UH2NS100121-01 | Arboleda-Velasquez, Joseph | SCHEPENS EYE RESEARCH INSTITUTE, MA | First-year cost $138,205 | Study section ZRG1 |
| FY2016 | Non-melanoma skin cancer: A model for impact of aging on an environmental disease1UH2CA213384-01 | Bickers, David Rinsey | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | First-year cost $120,000 | Study section ZRG1 |
| FY2016 | Recombinant Fc Chimeras of R-spondin 1 and Slit2 for Medical Countermeasure of Chronic Radiation Syndrome1UH2AI128900-01 | Geng, Jian-Guo | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | First-year cost $86,722 | Study section ZRG1 |
| FY2016 | Aged EFAD mice as a model for the effects of APOE and sex on AD pathology1UH2NS100127-01 | Ladu, Mary Jo | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | First-year cost $79,950 | Study section ZRG1 |
| FY2016 | Impact of aging on intestinal tumorigenesis1UH2CA213396-01 | Sabatini, David M. | WHITEHEAD INSTITUTE FOR BIOMEDICAL RES, MA | First-year cost $74,999 | Study section ZRG1 |
| FY2016 | Effect of aging on neuroinvasion during West Nile virus (WNV) infection.1UH2NS100126-01 | Diamond, Michael SKlein, Robyn S. | WASHINGTON UNIVERSITY, MO | First-year cost $74,817 | Study section ZRG1 |
| FY2016 | Impact of aging on progression and prevention of mammary preneoplasia and cancer1UH2CA213388-01 | Furth, Priscilla A. | GEORGETOWN UNIVERSITY, DC | First-year cost $74,388 | Study section ZRG1 |
| FY2016 | Probing the role of aging in basal cell carcinoma development and treatment response1UH2CA213386-01 | Dlugosz, Andrzej A. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | First-year cost $65,023 | Study section ZRG1 |
| FY2016 | Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion1UH2CA213392-01 | Li, Zhe | BRIGHAM AND WOMEN'S HOSPITAL, MA | First-year cost $60,000 | Study section ZRG1 |
| FY2016 | Age-Related Differences in Response to Radiation and Medical Countermeasures1UH2AI128894-01 | Orschell, Christie MPelus, Louis M | INDIANA UNIVERSITY INDIANAPOLIS, IN | First-year cost $52,081 | Study section ZRG1 |
| FY2016 | Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia1UH2CA213385-01 | Chen, Wenyong | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | First-year cost $51,410 | Study section ZRG1 |
| FY2016 | The effect of age on xenobiotic-induced autoimmunity1UH2ES027679-01 | Pollard, Kenneth Michael | SCRIPPS RESEARCH INSTITUTE, THE, CA | First-year cost $50,010 | Study section ZRG1 |
| FY2016 | Development of Immune-mediated Pulmonary Fibrosis in Older Mice1UH2ES027680-01 | Simonian, Philip Levon | UNIVERSITY OF COLORADO DENVER, CO | First-year cost $44,579 | Study section ZRG1 |
| FY2016 | Effect of Aging on Efficacy of Alzheimer-focused Therapeutic Strategies1UH2NS100128-01 | Mucke, Lennart | J. DAVID GLADSTONE INSTITUTES, CA | First-year cost $32,368 | Study section ZRG1 |
Newest fiscal year first, then first-year cost.
Patents from its funded projects
2 patents name 1 of the 14 funded projects.
- US 12,384,834 (opens the patent at USPTO, a PDF, in a new tab)ANTI-APOE ANTIBODIES AND POLYNUCLEOTIDES THEREOFGranted August 12, 2025 to The General Hospital Corporation, Banner Health and The Schepens Eye Research Institute, Inc.UH2NS100121 · SCHEPENS EYE RESEARCH INSTITUTE, MA
- US 11,229,662 (opens the patent at USPTO, a PDF, in a new tab)Compositions and Methods for the Treatment of Aberrant AngiogenesisGranted January 25, 2022 to The Schepens Eye Research Institute, Inc.UH2NS100121 · SCHEPENS EYE RESEARCH INSTITUTE, MA
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.